PharmaFluidics

Technologiepark 82

9052 Zwijnaarde

BE

PharmaFluidics

Foundation date

29/12/2020

Sector

#Supplier & Engineering

Subsector

The absence of molecular amplification in proteomics and metabolomics means that researchers rely heavily on sensitive detection of a biomarker during analytical separation. In recent years, LC performance has been the limiting factor in such experiments as the incremental improvement of conventional columns stalls. 

Based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems, PharmaFluidics introduces a new generation of chromatography columns. The company’s know-how is the design and manufacturing of miniaturized separation columns by silicon micromachining. The perfect order in the stationary phase leads to unique benefits in terms of performance, reproducibility and robustness.

PharmaFluidics was founded in 2010 as a spin-off from the University of Brussels (VUB).

Upcoming events

Latest news

  • Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

    Thursday November 30th 2023

  • Agomab appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

    Wednesday November 29th 2023

  • Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure

    Wednesday November 29th 2023